Groundbreaking study on FENBENDAZOLE published: Stage IV cancer patients in REMISSION – no chemo needed (2025)

News Report · Lance D Johnson · August 19, 2025

Lance D Johnson, 2025-08-19: The Aug 19 2025 NaturalNews article reports the Makis three-patient case series as a peer-reviewed study of stage IV patients in remission on fenbendazole as their primary treatment, and places it in 'Oncology Research and Treatment'.

documents three stage IV cancer patients, breast, prostate, and melanoma, who achieved complete or near-complete remission using fenbendazole (FBZ) as their primary treatment.

Lance D Johnson, 2025-08-19: The Aug 19 2025 NaturalNews article reports the Makis three-patient case series as a peer-reviewed study of stage IV patients in remission on fenbendazole as their primary treatment, and places it in 'Oncology Research and Treatment'. C5. Journal misattribution recorded plainly: the paper appeared in Case Reports in Oncology (Karger), not Oncology Research and Treatment. The article also asserts 'In 2021, Stanford researchers published a case series of three terminal cancer patients who used FBZ' – no such Stanford case series was found, and the three-patient series it goes on to describe is Makis's 2025 paper. Its claim that FBZ was 'their primary treatment' understates the concurrent therapies in the paper (fulvestrant and radiation in case 1, ADT in case 2, two nivolumab doses and surgery in case 3). The Alberta ban and Merck mRNA vaccine assertions are recorded as the article's own statements, not verified here. Study type: news.